<DOC>
	<DOCNO>NCT02467478</DOCNO>
	<brief_summary>Type 2 diabetes national epidemic . Diabetes undesirable effect blood vessel may contribute heart disease . Endothelial Progenitor Cells ( EPCs ) find blood . Research show improve survival special blood cell may decrease harmful effect diabetes blood vessel reduce reverse heart disease . Linagliptin Food Drug Administration ( FDA ) approve prescription medicine use along insulin oral medication low blood sugar people Type 2 diabetes . It class diabetes medication call Dipeptidyl peptidase-4 ( DPP-4 ) inhibitor . DPP-4 inhibitor show increase EPCs patient Type 2 diabetes . Hypothesis : Both type 2 diabetes Chronic Kidney Disease ( CKD ) associate poor stem cell number function . Poor viability function EPCs CKD diabetes The investigator hypothesize use Linagliptin ( along Insulin ) may help reduce cardiovascular risk improve EPC survival function beyond adequate glucose metabolism control</brief_summary>
	<brief_title>Linagliptin Effect CD34+ Stem Cells</brief_title>
	<detailed_description>Type 2 diabetes national epidemic significant macro microvascular complication . Insulin resistance pre-diabetes overt diabetes associate endothelial dysfunction . A study indicate stem cell particularly EPCs act suitable bio-marker monitoring cardiovascular morbidity . In proposal investigator suggest EPCs CD34 positive cell ( define CD34/vascular endothelial growth factor receptor 2 ( VEGFR2+ ) cell ) act suitable cellular biomarker estimate follow endothelial dysfunction early type 2 diabetes patient CKD . EPCs show dysfunctional CKD patient type 2 Diabetes Mellitus ( DM ) patient . Linagliptin ( TRADJENTA ) tablet indicate adjunct diet exercise improve glycemic control adult type 2 diabetes mellitus . No dose adjustment recommend patient renal impairment . EPCs use regenerative tool ischemic myocardium diabetic wound healing . Endothelial dysfunction associate inflammation may consequence excess intra-cellular super-oxide presence set diabetes pro-oxidative stress condition ultimately leading poor EPC function senescence . Though lifestyle modification propose main stay prevention treatment early type 2 diabetes , several new therapy diabetes developed recent year . Incretins incretin mimetics appear hold promise . Mechanism positive effect exercise oral hypoglycemic agent different . DPP-4 inhibitor show increase EPCs patient type 2 diabetes reportedly via stromal cell-derived factor 1 ( SDF-1 ) alpha up-regulation . Interestingly , up-regulation SDF-1 alpha vascular endothelial growth factor ( VEGF ) , chemotactic factor increase mobilization recruitment EPCs face acute ischemic injury repair regeneration . Several study show positive effect incretins ( Glucagon like peptide , GLP-1 ) incretin receptor agonist ( GLP-1 receptor agonist ) cardiovascular risk factor type 2 diabetes patient even patient chronic heart failure leave ventricular dysfunction diabetes . DPP-4 Inhibitors may cardio-protective effect , increase bio-availability endogenous GLP-1 . They improve blood flow nitric oxide production endothelium . These unique property demonstrate oral diabetes medication . The mechanism underlying effect may mediate increase nitric oxide bioavailability completely know . However beneficial effect appear independent glycemia reduction . It however unknown whether Linagliptin positive effect human EPC function two prominent cardiovascular risk factor co-exist CKD type 2 diabetes . Therefore investigator plan investigate Linagliptin alter function gene expression CD34+ cell set CKD type 2 diabetes . The investigator choose look non geriatric adult population early type 2 diabetes ( less 10 year duration ) early phase renal impairment ( stag 1-3 ) .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Adults age 4070 year Diagnosis type 2 diabetes within previous 10 year use criterion American Diabetes Association Currently treat 1.52 grams/day metformin , insulin , stably &gt; 3 month Hemoglobin A1c ( HbA1C ) 6.5 % 9.0 % ( inclusive ) Body Mass Index ( BMI ) 25 39.9 kg/m2 ( inclusive ) Chronic Kidney disease ( CKD ) Stages 13 , Creatinine clearance ( CrCl ) less 90 29 Type 1 diabetes History Diabetic Ketoacidosis ( DKA ) hyperosmolar nonketotic coma Hemoglobinopathies low hematocrit ( Below 28 Units ) History pancreatitis History cancer ( except basal cell carcinoma ) Previous cardiovascular cerebrovascular event within 6 month screen active clinically significant coronary and/or Peripheral Vascular Disease ( PVD ) Statin use start last 3 month Use oral injectable antidiabetic medication Metformin insulin Use form steroid medication ( oral , inhaled , inject ) within last 3 month Any active wound , surgery within past 3 month Inflammatory disease , chronic use antiinflammatory drug within past 3 month Untreated hyper/hypothyroidism Contraindications moderate exercise Implanted device might interact tanita scale Preexisting liver disease and/or Alanine aminotransferase ( ALT ) Aspartate Aminotransferase ( AST ) &gt; 2.5 time Under Normal Limits ( UNL ) Systolic blood pressure &gt; 140 mmHg diastolic blood pressure &gt; 90 mmHg Serum creatinine level â‰¥ 2.0 CKD Stages 4 5 ( estimate CrCl &lt; 30 mL/min ) Triglycerides &gt; 450 mg/dL Known allergy hypersensitivities Linagliptin Dipeptidyl peptidase4 ( DDP4 ) inhibitor Treatment cytochrome p450 ( CYP 3A4 ) inhibitor Women child bear age unwilling unable use acceptable method avoid pregnancy entire study Prisoners subject involuntarily incarcerate Subjects compulsorily detain treatment either psychiatric physical ( e.g . infectious disease ) illness Additionally , patient active smoker , patient pregnant , nurse woman , postmenopausal woman hormone replacement therapy exclude .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Endothelial cell</keyword>
	<keyword>Cellular biomarker</keyword>
	<keyword>endothelial dysfunction</keyword>
	<keyword>CD34+</keyword>
	<keyword>Impaired renal function</keyword>
</DOC>